A 68-year-old man presents with recurrent epigastric pain and recent-onset diabetes. Contrast-enhanced CT abdomen shows the lesion marked **A** in the diagram — diffuse dilatation of the main pancreatic duct to 9 mm with multiple small cystic outpouchings communicating with the duct, no surrounding inflammation, and a bulging papilla. Serum amylase is normal; CA 19-9 is mildly elevated. Based on the imaging findings and clinical presentation, which of the following is the most appropriate next step in management?
A. Endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy and observation
B. Surgical resection (distal or total pancreatectomy depending on extent)
C. Magnetic resonance cholangiopancreatography (MRCP) follow-up at 6 months
D. Conservative management with proton pump inhibitors and diabetes control
Explanation
Why Surgical resection is right
The structure marked A — main-duct IPMN with diffuse pancreatic duct dilatation (>5 mm) and communicating cystic outpouchings — is a mucin-producing epithelial tumor of the pancreatic ductal system with HIGH MALIGNANT POTENTIAL (~60–70% invasive carcinoma risk). Per the Fukuoka/Kyoto IPMN guidelines, main-duct IPMN is a SURGICAL INDICATION regardless of symptoms or worrisome features, because resection before invasive transformation is curative. The clinical presentation (epigastric pain, new-onset diabetes) and imaging findings (bulging papilla, mildly elevated CA 19-9, normal amylase) are classic for main-duct IPMN. Surgical resection (distal or total pancreatectomy depending on extent of duct involvement) is the standard of care.
Why each distractor is wrong
ERCP with sphincterotomy and observation: While ERCP can confirm the diagnosis (fish-mouth ampulla), it is NOT curative and does not address the high malignant potential. Observation alone is inappropriate for main-duct IPMN; this approach is reserved for branch-duct IPMN without high-risk stigmata.
MRCP follow-up at 6 months: Surveillance imaging is not indicated for main-duct IPMN. Delaying surgery increases the risk of invasive transformation and reduces curability. This approach would be considered for branch-duct IPMN with worrisome features, not main-duct disease.
Conservative management with PPI and diabetes control: Symptomatic and imaging-confirmed main-duct IPMN requires definitive treatment. Medical management alone does not prevent malignant transformation and is inappropriate for a surgical lesion.
High-YieldNEET PG
Main-duct IPMN (duct >5 mm, communicating cysts, no obstructing mass) = HIGH malignant potential (~60–70%) = SURGICAL INDICATION per Fukuoka/Kyoto guidelines. Branch-duct IPMN without high-risk stigmata = surveillance.
Bosniak/Kyoto IPMN Guidelines 2024; Fukuoka consensus criteria for IPMN management
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
